AAM Statement on the Anniversary of USMCA
WASHINGTON DC (July 1, 2021) – On the occasion of the one-year anniversary of the U.S.-Mexico-Canada Agreement coming into force, the Association for Accessible Medicines (AAM) releases the following statement: One year ago today, the U.S.-Mexico-Canada Agreement set the standard for a modern trade agreement. By balancing support for pharmaceutical innovation with generic and biosimilar […]
USMCA Trade Agreement: A Victory for America’s Patients — #FixedUSMCA
AAM is pleased that Congress and the Administration have made changes to USMCA that support open markets, greater competition and improved cost savings for patients and the three health care systems. The revised USMCA trade agreement creates greater opportunities for patients in Mexico, Canada and the United States to access less expensive medicines and promotes […]
The USMCA Will Keep Drug Prices Out of Reach for Patients, But Congress Can Fix It
The USMCA Creates New Barriers, Delays Patient Access to Affordable Medicines — Especially Biosimilars. The Agreement would delay U.S. patient access to competition from low-cost, high-quality generic and biosimilar medicines, and fails to include strong incentives for their approval and uptake. Read Full Brief
AAM Statement on USTR Lighthizer’s House Testimony on USMCA
WASHINGTON, DC (June 18, 2020) — The Association for Accessible Medicines (AAM) welcomed U.S. Trade Representative Ambassador Robert Lighthizer’s commitment during his testimony yesterday before the House Ways and Means Committee that the free trade agreement currently being negotiated, including with the United Kingdom, will not contain a provision requiring 10-years of biologic exclusivity. “USMCA’s pharmaceutical […]
AAM and Sister Associations in Canada and Mexico: Governments Should Not Raise Drug Prices in Renegotiated NAFTA
WASHINGTON, DC (September 19, 2017) – The Association for Accessible Medicines, the Canadian Generic Pharmaceutical Association and the Mexican Association of Generic Medicines are urging their three governments not to raise drug prices for patients by extending monopolies for brand name medicines and biologics under a renegotiated North American Trade Agreement (NAFTA). In a letter […]
AAM Statement on Signing USMCA into Law
WASHINGTON DC (January 29, 2020) – “The Association for Accessible Medicines applauds President Trump’s signing of the U.S.-Mexico-Canada Agreement, the new gold standard for free trade agreements. Not only will patients have greater access to affordable medicines as a result of the USMCA, but America’s patients can be assured that this agreement promotes competition, access […]
AAM Statement on Senate Passage of USMCA Agreement
WASHINGTON DC (January 16, 2020) – “The Association for Accessible Medicines strongly endorses the Senate’s bipartisan passage of the U.S.-Mexico-Canada Agreement. For the first time in a trade agreement, a balance between support for innovation and access to affordable medicines has been reached. This balance will not only allow the growth of U.S. brand, generic […]
USMCA Sets a New Standard for Lowering Drug Prices and Expanding Access to Medicines
WASHINGTON DC (December 19, 2019) – “The Association for Accessible Medicines applauds the House of Representatives’ overwhelming bipartisan passage of the U.S.-Mexico-Canada Agreement. The vote was 385 to 41. By including provisions that promote generic and biosimilar competition, patients in all three countries will benefit from a market where generic and biosimilar medicines can compete […]
USMCA Trade Agreement: A Victory for America’s Patients
WASHINGTON DC (December 10, 2019) – Today’s agreement reached by the Congressional Trade Working Group and the Trump administration represents a victory for patients. The revised text creates greater opportunities for patients in Mexico, Canada and the United States to access less expensive medicines and promotes a competitive pharmaceutical market across the three countries. The […]
Myths vs. Facts of Biologic Market Exclusivity in Mexico — #FixUSMCA
The pharmaceutical provisions included in the negotiated text of the U.S.-Mexico-Canada Agreement will do many things. But creating a market for biologics in Mexico is not one of them. Why? Because pharmaceutical companies have been selling original biologics in Mexico since before 2001. Mexico, based on drug regulator COFEPRIS’s policy, provides five-years of data exclusivity […]
The House Has Spoken – It’s Time to Fix USMCA’s Pharmaceutical Provisions
In a letter given to U.S. Trade Representative Robert Lighthizer today, 102 members of the House of Representatives expressed strong concern that the pharmaceutical provisions included in the U.S.-Mexico-Canada Agreement (USMCA) – NAFTA 2.0 – could increase prices for medicines in the United States, while limiting the ability of Congress to lessen pharmaceutical monopoly rights. This […]
Highlights from the NAFTA 2.0 Congressional Briefing: The May 10 Amendments
On May 10, 2019, the Association for Accessible Medicines (AAM) hosted a briefing for congressional staff and other stakeholders on the twelfth anniversary of the May 10 Agreement, the bipartisan agreement to reopen the Colombia, Panama, Peru and South Korea trade agreements to address labor, environment and access to medicines issues. The briefing, which included remarks […]
